MedTrace Logo

Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss

NCT02345031 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2018-08-09

Study results available
· View outcomes & findings →

Summary

This study aims to demonstrate that the investigational drug AUT00063 is effective and safe in the treatment of age-related hearing loss.

Conditions

  • Age-Related Hearing Loss

Interventions

DRUG

AUT00063

600 mg, orally, once a day, for 4 weeks

DRUG

Placebo

orally, once a day, for 4 weeks

Sponsors & Collaborators

  • Autifony Therapeutics Limited

    lead INDUSTRY

Principal Investigators

  • Robert Frisina, PhD · Director Global Center for Hearing and Speech Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-05-31
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02345031 on ClinicalTrials.gov